Literature DB >> 10634356

Long-term treatment of prolactin-secreting macroadenomas with pergolide.

P U Freda1, C I Andreadis, A G Khandji, M Khoury, J N Bruce, T P Jacobs, S L Wardlaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10634356     DOI： 10.1210/jcem.85.1.6329

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  11 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 4.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

5.  Pergolide as primary therapy for macroprolactinomas.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

6.  Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.

Authors:  J J Orrego; W F Chandler; A L Barkan
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

Review 7.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 8.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

9.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

Review 10.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.